vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and SIMMONS FIRST NATIONAL CORP (SFNC). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $197.3M, roughly 1.4× SIMMONS FIRST NATIONAL CORP). On growth, SIMMONS FIRST NATIONAL CORP posted the faster year-over-year revenue change (19.6% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 0.6%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Simmons Bank is a bank with operations in Arkansas, Kansas, Missouri, Oklahoma, Tennessee, and Texas. It is the primary subsidiary of Simmons First National Corporation, a bank holding company.
ACAD vs SFNC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $197.3M |
| Net Profit | $273.6M | — |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | — |
| Net Margin | 96.3% | — |
| Revenue YoY | 9.4% | 19.6% |
| Net Profit YoY | 90.3% | — |
| EPS (diluted) | $1.61 | $0.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $197.3M | ||
| Q3 25 | $278.6M | $186.7M | ||
| Q2 25 | $264.6M | $214.2M | ||
| Q1 25 | $244.3M | $209.6M | ||
| Q4 24 | $259.6M | $208.5M | ||
| Q3 24 | $250.4M | $174.8M | ||
| Q2 24 | $242.0M | $197.2M | ||
| Q1 24 | $205.8M | $195.1M |
| Q4 25 | $273.6M | — | ||
| Q3 25 | $71.8M | $-562.8M | ||
| Q2 25 | $26.7M | $54.8M | ||
| Q1 25 | $19.0M | $32.4M | ||
| Q4 24 | $143.7M | — | ||
| Q3 24 | $32.8M | $24.7M | ||
| Q2 24 | $33.4M | $40.8M | ||
| Q1 24 | $16.6M | $38.9M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | — | ||
| Q3 25 | 12.8% | — | ||
| Q2 25 | 12.2% | — | ||
| Q1 25 | 7.9% | — | ||
| Q4 24 | 59.1% | — | ||
| Q3 24 | 12.6% | — | ||
| Q2 24 | 12.6% | — | ||
| Q1 24 | 7.4% | — |
| Q4 25 | 96.3% | — | ||
| Q3 25 | 25.8% | -301.5% | ||
| Q2 25 | 10.1% | 25.6% | ||
| Q1 25 | 7.8% | 15.5% | ||
| Q4 24 | 55.4% | — | ||
| Q3 24 | 13.1% | 14.1% | ||
| Q2 24 | 13.8% | 20.7% | ||
| Q1 24 | 8.0% | 19.9% |
| Q4 25 | $1.61 | $0.36 | ||
| Q3 25 | $0.42 | $-4.00 | ||
| Q2 25 | $0.16 | $0.43 | ||
| Q1 25 | $0.11 | $0.26 | ||
| Q4 24 | $0.86 | $0.38 | ||
| Q3 24 | $0.20 | $0.20 | ||
| Q2 24 | $0.20 | $0.32 | ||
| Q1 24 | $0.10 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | — |
| Total DebtLower is stronger | — | $620.0M |
| Stockholders' EquityBook value | $1.2B | $3.4B |
| Total Assets | $1.6B | $24.5B |
| Debt / EquityLower = less leverage | — | 0.18× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | — | ||
| Q3 25 | $258.0M | — | ||
| Q2 25 | $253.6M | — | ||
| Q1 25 | $217.7M | — | ||
| Q4 24 | $319.6M | — | ||
| Q3 24 | $155.1M | — | ||
| Q2 24 | $177.1M | — | ||
| Q1 24 | $204.7M | — |
| Q4 25 | — | $620.0M | ||
| Q3 25 | — | $667.8M | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | — | $1.2B |
| Q4 25 | $1.2B | $3.4B | ||
| Q3 25 | $917.3M | $3.4B | ||
| Q2 25 | $822.4M | $3.5B | ||
| Q1 25 | $765.2M | $3.5B | ||
| Q4 24 | $732.8M | $3.5B | ||
| Q3 24 | $577.2M | $3.5B | ||
| Q2 24 | $516.7M | $3.5B | ||
| Q1 24 | $464.0M | $3.4B |
| Q4 25 | $1.6B | $24.5B | ||
| Q3 25 | $1.3B | $24.2B | ||
| Q2 25 | $1.2B | $26.7B | ||
| Q1 25 | $1.1B | $26.8B | ||
| Q4 24 | $1.2B | $26.9B | ||
| Q3 24 | $976.9M | $27.3B | ||
| Q2 24 | $914.1M | $27.4B | ||
| Q1 24 | $855.1M | $27.4B |
| Q4 25 | — | 0.18× | ||
| Q3 25 | — | 0.20× | ||
| Q2 25 | — | 0.28× | ||
| Q1 25 | — | 0.35× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.40× | ||
| Q2 24 | — | 0.50× | ||
| Q1 24 | — | 0.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $449.5M |
| Free Cash FlowOCF − Capex | — | $411.4M |
| FCF MarginFCF / Revenue | — | 208.5% |
| Capex IntensityCapex / Revenue | — | 19.3% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $717.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $449.5M | ||
| Q3 25 | $74.3M | $223.4M | ||
| Q2 25 | $64.0M | $77.6M | ||
| Q1 25 | $20.3M | $32.8M | ||
| Q4 24 | $40.4M | $425.9M | ||
| Q3 24 | $63.2M | $199.4M | ||
| Q2 24 | $25.0M | $86.1M | ||
| Q1 24 | $29.1M | $57.6M |
| Q4 25 | — | $411.4M | ||
| Q3 25 | $73.9M | $216.7M | ||
| Q2 25 | — | $66.3M | ||
| Q1 25 | — | $22.6M | ||
| Q4 24 | — | $380.4M | ||
| Q3 24 | $63.2M | $187.7M | ||
| Q2 24 | — | $72.7M | ||
| Q1 24 | — | $47.7M |
| Q4 25 | — | 208.5% | ||
| Q3 25 | 26.5% | 116.1% | ||
| Q2 25 | — | 31.0% | ||
| Q1 25 | — | 10.8% | ||
| Q4 24 | — | 182.5% | ||
| Q3 24 | 25.2% | 107.4% | ||
| Q2 24 | — | 36.9% | ||
| Q1 24 | — | 24.5% |
| Q4 25 | — | 19.3% | ||
| Q3 25 | 0.1% | 3.6% | ||
| Q2 25 | — | 5.3% | ||
| Q1 25 | — | 4.8% | ||
| Q4 24 | — | 21.8% | ||
| Q3 24 | 0.0% | 6.7% | ||
| Q2 24 | — | 6.8% | ||
| Q1 24 | — | 5.0% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | 1.42× | ||
| Q1 25 | 1.07× | 1.01× | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | 8.06× | ||
| Q2 24 | 0.75× | 2.11× | ||
| Q1 24 | 1.76× | 1.48× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
SFNC
Segment breakdown not available.
